It modulates the levels of ferroptosis-related signaling pathways, including ACSL4, SLC7A11, GPX4, and FTH1, and reduces the expression of MMP3 and MMP13, which could be one of the important mechanisms and pathways underlying its inhibitory effect on RA bone destruction. The gene discussed is GPX4; the disease is rheumatoid arthritis.